Literature DB >> 22644330

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.

A Rostami-Hodjegan1.   

Abstract

Classic pharmacokinetics (PK) rarely takes into account the full knowledge of physiology and biology of the human body. However, physiologically based PK (PBPK) is built mainly from drug-independent "system" information. PBPK is not a new concept, but it has shown a very rapid rise in recent years. This has been attributed to a greater connectivity to in vitro-in vivo extrapolation (IVIVE) techniques for predicting drug absorption, distribution, metabolism, and excretion (ADME) and their variability in humans. The marriage between PBPK and IVIVE under the overarching umbrella of "systems biology" has removed many constraints related to cutoff approaches on prediction of ADME. PBPK-IVIVE linked models have repeatedly shown their value in guiding decisions when predicting the effects of intrinsic and extrinsic factors on PK of drugs. A review of the achievements and shortcomings of the models might suggest better strategies in extending the success of PBPK-IVIVE to pharmacodynamics (PD) and drug safety.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644330     DOI: 10.1038/clpt.2012.65

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  99 in total

1.  Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.

Authors:  Els Van Peer; Noel Downes; Christophe Casteleyn; Chris Van Ginneken; Arie Weeren; Steven Van Cruchten
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-19       Impact factor: 2.745

Review 2.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 3.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

4.  FutureTox: building the road for 21st century toxicology and risk assessment practices.

Authors:  J Craig Rowlands; Miriam Sander; James S Bus
Journal:  Toxicol Sci       Date:  2013-11-07       Impact factor: 4.849

5.  Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.

Authors:  Ling Song; Yi Zhang; Ji Jiang; Shuang Ren; Li Chen; Dongyang Liu; Xijing Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

6.  Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.

Authors:  Christian Wagner; Yuzhuo Pan; Vicky Hsu; Joseph A Grillo; Lei Zhang; Kellie S Reynolds; Vikram Sinha; Ping Zhao
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

7.  Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.

Authors:  Christian Wagner; Ping Zhao; Vikram Arya; Charu Mullick; Kimberly Struble; Stanley Au
Journal:  J Clin Pharmacol       Date:  2017-06-01       Impact factor: 3.126

Review 8.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

9.  Challenges and opportunities in the advancement of nanomedicines.

Authors:  Alexander Wei; Jonathan G Mehtala; Anil K Patri
Journal:  J Control Release       Date:  2012-10-12       Impact factor: 9.776

10.  A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.

Authors:  Jing-Tao Lu; Ying Cai; Feng Chen; Wei-Wei Jia; Zhe-Yi Hu; Yuan-Sheng Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.